Article
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2016
Lucena-Araujo Antonio R, Moran Jason P, VanderLaan Paul A, Dias-Santagata Dora, Folch Erik, Majid Adnan, Kent Michael S, Gangadharan Sidharta P, Rangachari Deepa, Huberman Mark S, Kobayashi Susumu S, Costa Daniel B
Abstract excerpt
INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearranged lung adenocarcinomas are responsive to the multitargeted ALK inhibitor crizotinib. One of the common mechanisms of resistance to crizotinib is the acquisition of ALK kinase domain mutations. However, the presence of ALK mutations in crizotinib-naïve tumors has not been widely reported and it is unclear if de novo ALK mutations affect the response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.